Ligand Announces Closing of Convertible Senior Notes Offering
Ligand Pharmaceuticals closed a $700 million offering of 0.00% convertible senior notes due 2031, generating net proceeds of approximately $678.2 million. The company allocated about $72.9 million to hedge transactions and repurchased 228,859 shares of common stock for $60.0 million at a price of $262.17 per share to offset potential dilution upon conversion.
Key figures
- Deal Value Usd
- 700000000
- Hedge cost
- $72.9 million
- Coupon rate
- 0.00%
- Net proceeds
- $678.2 million
- Buyback price
- $262.17
- Buyback amount
- $60.0 million
- Shares repurchased
- 228859
- Warrant strike price
- $524.34
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.